Clinically relevant test methods to establish in vitro equivalence for spacers and valved holding chambers used with pressurized metered dose inhalers (pMDIs).
暂无分享,去创建一个
[1] R. Dhand,et al. Gross and subgross anatomy of bronchial circulation in sheep. , 1984, Journal of applied physiology: respiratory, environmental and exercise physiology.
[2] S. Newman,et al. How well do in vitro particle size measurements predict drug delivery in vivo? , 1998, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.
[3] J. Virchow,et al. Inhaler choice in primary practice , 2005, European Respiratory Review.
[4] H. Tiddens,et al. Effect of a facemask leak on aerosol delivery from a pMDI-spacer system. , 2004, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.
[5] Pierre Ernst,et al. Canadian asthma consensus report, 1999 , 1999 .
[6] R. Ahrens,et al. Choosing the metered-dose inhaler spacer or holding chamber that matches the patient's need: evidence that the specific drug being delivered is an important consideration. , 1995, The Journal of allergy and clinical immunology.
[7] P. Barry,et al. The effect of delay, multiple actuations and spacer static charge on the in vitro delivery of budesonide from the Nebuhaler. , 1995, British journal of clinical pharmacology.
[8] Jolyon Mitchell,et al. Adapting the Abbreviated Impactor Measurement (AIM) concept to make appropriate inhaler aerosol measurements to compare with clinical data: a scoping study with the "Alberta" idealized throat (AIT) inlet. , 2012, Journal of aerosol medicine and pulmonary drug delivery.
[9] M. Nagel,et al. The Abbreviated Impactor Measurement (AIM) Concept: Part II—Influence of Evaporation of a Volatile Component—Evaluation with a “Droplet-Producing” Pressurized Metered Dose Inhaler (pMDI)-Based Formulation Containing Ethanol as Cosolvent , 2009, AAPS PharmSciTech.
[10] B. Lipworth,et al. Early lung absorption profile of non-CFC salbutamol via small and large volume plastic spacer devices. , 1998, British journal of clinical pharmacology.
[11] N. Barnes. The properties of inhaled corticosteroids: similarities and differences. , 2007, Primary care respiratory journal : journal of the General Practice Airways Group.
[12] S. Dissanayake. Application of the EU Guidelines for Pharmacokinetic Studies of Locally Acting Orally Inhaled Drug Products , 2010 .
[13] P. Rhodes. Administration. , 1933, Teachers College Record: The Voice of Scholarship in Education.
[14] R. Woodhouse,et al. Pharmaceutical transition to non-CFC pressurized metered dose inhalers. , 2000, Respiratory medicine.
[15] K. Nikander,et al. Variation in pediatric aerosol delivery: importance of facemask. , 2005, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.
[16] Virgil A Marple,et al. Next generation pharmaceutical impactor (a new impactor for pharmaceutical inhaler testing). Part II: Archival calibration. , 2003, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.
[17] B. Laube,et al. The efficacy of slow versus faster inhalation of cromolyn sodium in protecting against allergen challenge in patients with asthma. , 1998, The Journal of allergy and clinical immunology.
[18] A brief history of gamma scintigraphy. , 2001, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.
[19] H. Bisgaard. A metal aerosol holding chamber devised for young children with asthma. , 1995, The European respiratory journal.
[20] Ola Nerbrink,et al. Laser diffractometry as a technique for the rapid assessment of aerosol particle size from inhalers. , 2006, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.
[21] H. Chrystyn. Methods to identify drug deposition in the lungs following inhalation. , 2001, British journal of clinical pharmacology.
[22] Rm Evans,et al. Aerosol generation from propellant-driven metered dose inhalers , 1995 .
[23] M. Dolovich,et al. In vitro estimations of in vivo jet nebulizer efficiency using actual and simulated tidal breathing patterns. , 2005, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.
[24] H. Chrystyn,et al. Relative bioavailability of salbutamol to the lung following inhalation when administration is prolonged. , 2000, British journal of clinical pharmacology.
[25] Jolyon P. Mitchell,et al. Size analysis of a pressurized metered dose inhaler-delivered solution formulation by an Aerosizer-LD time-of-flight aerosol particle size spectrometer. , 2002, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.
[26] G. Pitcairn,et al. Deposition and pharmacokinetics of flunisolide delivered from pressurized inhalers containing non-CFC and CFC propellants. , 2001, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.
[27] J. Soberman,et al. Salmeterol administration by metered-dose inhaler alone vs metered-dose inhaler plus valved holding chamber. , 2000, Chest.
[28] J. L. Rau,et al. Device selection and outcomes of aerosol therapy: Evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. , 2005, Chest.
[29] Jolyon P. Mitchell,et al. Development and Calibration of a Low-Flow Version of the Marple-Miller Impactor (MMI™) , 1998 .
[30] Hak-Kim Chan,et al. In vitro/in vivo comparisons in pulmonary drug delivery. , 2008, Journal of aerosol medicine and pulmonary drug delivery.
[31] W. Finlay. Inertial sizing of aerosol inhaled during pediatric tidal breathing from an MDI with attached holding chamber , 1998 .
[32] Graham K Crompton,et al. How to achieve good compliance with inhaled asthma therapy. , 2004, Respiratory medicine.
[33] Benjamin Y. H. Liu,et al. Characteristics of laminar jet impactors , 1974 .
[34] Svetlana Lyapustina,et al. Demonstrating Bioequivalence of Locally Acting Orally Inhaled Drug Products (OIPs): Workshop Summary Report. , 2010, Journal of aerosol medicine and pulmonary drug delivery.
[35] H. Bisgaard,et al. A non-electrostatic spacer for aerosol delivery. , 1995, Archives of disease in childhood.
[36] P. N. Souëf,et al. Spacer inhalation technique and deposition of extrafine aerosol in asthmatic children , 2006, European Respiratory Journal.
[37] Warren H. Finlay,et al. On the suitability of k–ε turbulence modeling for aerosol deposition in the mouth and throat: a comparison with experiment , 2000 .
[38] Y. Cheng,et al. Respiratory deposition patterns of salbutamol pMDI with CFC and HFA-134a formulations in a human airway replica. , 2001, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.
[39] G. Rudolf,et al. Modelling and algebraic formulation of regional aerosol deposition in man , 1990 .
[40] P. O'Byrne,et al. Clinical models to compare the safety and efficacy of inhaled corticosteroids in patients with asthma. , 2003, Canadian respiratory journal.
[41] B. Lipworth,et al. Pharmacokinetics of inhaled drugs. , 2003, British journal of clinical pharmacology.
[42] I. Amirav. Infant aerosol holding chamber face masks: not all are born equal! , 2006, Respiratory care.
[43] D. O’Donnell. What is unique about the new Canadian COPD guidelines? , 2004, Canadian respiratory journal.
[44] Effect of Oropharyngeal Length in Drug Lung Delivery via Suspension Pressurized Metered Dose Inhalers , 2006, Pharmaceutical Research.
[45] M. Newhouse,et al. Dead space variability of face masks for valved holding chambers. , 2008, The Israel Medical Association journal : IMAJ.
[46] M. Dolovich,et al. Impact of oropharyngeal deposition on inhaled dose. , 1998, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.
[47] Bruce K Rubin,et al. Optimizing aerosol delivery by pressurized metered-dose inhalers. , 2005, Respiratory care.
[48] M. Newhouse,et al. Design and characteristics of a portable breath actuated, particle size selective medical aerosol inhaler , 1982 .
[49] Svetlana Lyapustina,et al. Product Quality Research Institute evaluation of cascade impactor profiles of pharmaceutical aerosols: Part 2—Evaluation of a method for determining equivalence , 2008, AAPS PharmSciTech.
[50] Svetlana Lyapustina,et al. Product Quality Research Institute evaluation of cascade impactor profiles of pharmaceutical aerosols, part 1: Background for a statistical method , 2007, AAPS PharmSciTech.
[51] Jolyon P Mitchell,et al. Appropriate face models for evaluating drug delivery in the laboratory: the current situation and prospects for future advances. , 2008, Journal of aerosol medicine and pulmonary drug delivery.
[52] W. Finlay,et al. Regional aerosol deposition and flow measurements in an idealized mouth and throat , 2004 .
[53] Stephen W. Stein,et al. The Relative Influence of Atomization and Evaporation on Metered Dose Inhaler Drug Delivery Efficiency , 2006 .
[54] M. Dolovich,et al. Canadian Standards Association standard CAN/CSA/Z264.1-02:2002: a new voluntary standard for spacers and holding chambers used with pressurized metered-dose inhalers. , 2004, Canadian respiratory journal.
[55] R. Ahrens. The role of the MDI and DPI in pediatric patients: "Children are not just miniature adults". , 2005, Respiratory care.
[56] J. Mitchell,et al. In vitro performance testing of three small volume-holding chambers under conditions that correspond with use by infants and small children. , 1997, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.
[57] P. Barry,et al. A comparative analysis of the particle size output of beclomethasone diproprionate, salmeterol xinafoate and fluticasone propionate metered dose inhalers used with the Babyhaler, Volumatic and Aerochamber spacer devices. , 1999, British journal of clinical pharmacology.
[58] Journals Ltd,et al. Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone , 1998 .
[59] D. R. Allanson,et al. The Interaction Between the Oropharyngeal Geometry and Aerosols via Pressurised Metered Dose Inhalers , 2009, Pharmaceutical Research.
[60] C. Quale,et al. Minimizing Variability of Cascade Impaction Measurements in Inhalers and Nebulizers , 2008, AAPS PharmSciTech.
[61] Scott A Foss,et al. In vitro testing of MDI spacers : A technique for measuring respirable dose output with actuation in-phase or out-of-phase with inhalation , 1999 .
[62] K. Looi,et al. Validation of methodology for recording breathing and simulating drug delivery through spacers and valved holding chambers. , 2010, Journal of aerosol medicine and pulmonary drug delivery.
[63] Stephen W. Stein,et al. SELECTION AND VALIDATION OF CASCADE IMPACTOR TEST METHODS , 2004 .
[64] D. Brooks,et al. State of the Art Compendium: Canadian Thoracic Society recommendations for the management of chronic obstructive pulmonary disease. , 2004, Canadian respiratory journal.
[65] Gerald C. Smaldone,et al. Drug Delivery to the Lung , 2001 .
[66] W. Fokkens,et al. The Sophia Anatomical Infant Nose-Throat (Saint) model: a valuable tool to study aerosol deposition in infants. , 2001, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.
[67] J Stocks,et al. Structure and function of the respiratory system: Developmental aspects and their relevance to aerosol therapy , 2002 .
[68] S. Stein. Estimating the Number of Droplets and Drug Particles Emitted from MDIs , 2008, AAPS PharmSciTech.
[69] C. Camargo,et al. Consensus statement: aerosols and delivery devices. American Association for Respiratory Care. , 2000, Respiratory care.
[70] M J Connolly. Inhaler technique of elderly patients: comparison of metered-dose inhalers and large volume spacer devices. , 1995, Age and ageing.
[71] M. Dolovich. Aerosol delivery to children: What to use, how to choose , 1999, Pediatric pulmonology. Supplement.
[72] M. Dolovich. Characterization of medical aerosols: physical and clinical requirements for new inhalers , 1995 .
[73] P. Barry,et al. In vitro comparison of the amount of salbutamol available for inhalation from different formulations used with different spacer devices. , 1997, The European respiratory journal.
[74] Jolyon P Mitchell,et al. Cascade impactors for the size characterization of aerosols from medical inhalers: their uses and limitations. , 2003, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.
[75] Stephen W. Stein,et al. Aiming for a moving target: challenges with impactor measurements of MDI aerosols. , 2008, International journal of pharmaceutics.
[76] Jolyon P Mitchell,et al. Valved holding chambers (VHCs) for use with pressurised metered-dose inhalers (pMDIs): a review of causes of inconsistent medication delivery. , 2007, Primary care respiratory journal : journal of the General Practice Airways Group.
[77] S. Newman. Inhaler treatment options in COPD , 2005, European Respiratory Review.
[78] C. Camargo,et al. Consensus statement: aerosols and delivery devices. , 2000, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.
[79] R. Pauwels,et al. Variability in lung deposition of inhaled drug, within and between asthmatic patients, with a pMDI and a dry powder inhaler, Turbuhaler. , 2000, International journal of pharmaceutics.
[80] J. Wildhaber,et al. High‐percentage lung delivery in children from detergent‐treated spacers , 2000, Pediatric pulmonology.
[81] Svetlana Lyapustina,et al. Non-impactor-Based Methods for Sizing of Aerosols Emitted from Orally Inhaled and Nasal Drug Products (OINDPs) , 2011, AAPS PharmSciTech.
[82] H. Bisgaard,et al. Lung function measurement in awake young children. , 1995, The European respiratory journal.
[83] Svetlana Lyapustina,et al. Considerations for the development and practice of cascade impaction testing, including a mass balance failure investigation tree. , 2003, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.
[84] J. Mitchell,et al. Time-of-flight aerodynamic particle size analyzers: their use and limitations for the evaluation of medical aerosols. , 1999, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.
[85] D. Pavia,et al. How should a pressurized beta-adrenergic bronchodilator be inhaled? , 1981, European journal of respiratory diseases.
[86] J. L. Rau,et al. The importance of nonelectrostatic materials in holding chambers for delivery of hydrofluoroalkane albuterol. , 2006, Respiratory care.
[87] J. Fink,et al. Metered-dose inhalers, dry powder inhalers, and transitions. , 2000, Respiratory care.
[88] Svetlana Lyapustina,et al. Product quality research institute evaluation of cascade impactor profiles of pharmaceutical aerosols, part 3: Final report on a statistical procedure for determining equivalence , 2008, AAPS PharmSciTech.
[89] Samir A. Shah,et al. Force-dependent static dead space of face masks used with holding chambers. , 2006, Respiratory care.
[90] W. Seeger,et al. Inhaled prostanoids in the therapy of pulmonary hypertension. , 2008, Journal of aerosol medicine and pulmonary drug delivery.
[91] J. Oppenheimer. Device Selection and Outcomes of Aerosol Therapy: Evidence-Based Guidelines , 2006 .
[92] W. Finlay,et al. In vitro effect of a holding chamber on the mouth-throat deposition of QVAR (hydrofluoroalkane-beclomethasone dipropionate). , 2002, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.
[93] A. Fuglsang,et al. Role of pharmacokinetics in establishing bioequivalence for orally inhaled drug products: workshop summary report. , 2011, Journal of aerosol medicine and pulmonary drug delivery.
[94] G. Colice,et al. A pilot study to assess lung deposition of HFA-beclomethasone and CFC-beclomethasone from a pressurized metered dose inhaler with and without add-on spacers and using varying breathhold times. , 2010, Journal of aerosol medicine and pulmonary drug delivery.
[95] G. Rachelefsky,et al. Impact of inhaled corticosteroid-induced oropharyngeal adverse events: results from a meta-analysis. , 2007, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[96] Kumaragovindhan Santhanakrishnan,et al. Next generation pharmaceutical impactor: a new impactor for pharmaceutical inhaler testing. Part III. extension of archival calibration to 15 L/min. , 2004, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.
[97] G. Hochhaus. New developments in corticosteroids. , 2004, Proceedings of the American Thoracic Society.
[98] M. Dolovich,et al. Delivery of HFA and CFC salbutamol from spacer devices used in infancy. , 2001, International journal of pharmaceutics.
[99] S. K. Tee,et al. Drug Delivery to the Lungs XI , 2001 .
[100] Warren H. Finlay,et al. The Mechanics of Inhaled Pharmaceutical Aerosols: An Introduction , 2001 .
[101] J. Wildhaber,et al. Washing plastic spacers in household detergent reduces electrostatic charge and greatly improves delivery. , 1999, The European respiratory journal.
[102] M. Dolovich,et al. Lung dose, distribution, and clinical response to therapeutic aerosols , 1993 .
[103] J. Dubus,et al. The ADMIT series--issues in inhalation therapy. 5) Inhaler selection in children with asthma. , 2010, Primary care respiratory journal : journal of the General Practice Airways Group.
[104] Jolyon Mitchell,et al. In vitro and in vivo aspects of cascade impactor tests and inhaler performance: A review , 2007, AAPS PharmSciTech.